KIT Mutation Results Explained

exon 9, 11, 13 and 17 changes in GIST and melanoma

What each line of the report means

Specimen: Tumor tissue, as stated
KIT testing is central to gastrointestinal stromal tumor (GIST) diagnosis and treatment selection.
Biomarker / finding: Exon 11 mutation
The exon number is the result: exon 11, 9, 13 and 17 changes respond differently to imatinib and later-line drugs.
Classification: Pathogenic, Tier I
KIT mutations are established drivers in GIST and a subset of melanomas.
Clinical interpretation: Exon-specific review required
Exon 9 mutations often need higher imatinib dosing; exon 17/18 changes can signal resistance.

How this result is interpreted

  • About 80-85% of GISTs carry a KIT mutation, and the exon location predicts drug sensitivity - this is one of oncology's clearest genotype-to-drug maps.
  • Exon 11 mutations are generally imatinib-sensitive; exon 9 mutations often benefit from a higher imatinib dose; secondary exon 13/14 and 17/18 mutations drive resistance and guide later-line choices.
  • KIT-mutant melanoma (a small subset, often acral or mucosal) can respond to KIT inhibitors - one of the few targeted options in those melanoma types.

What this result cannot tell you

  • A negative KIT result does not exclude GIST - some GISTs are driven by PDGFRA or other alterations, and SDH-deficient GIST is mutation-negative.
  • Resistance mutations can appear only in progressing lesions; a blood or new-lesion biopsy may show changes the original sample did not.
  • Dose and drug selection from exon results should follow current GIST-specific guidelines.

Questions to ask your oncologist

  • Which exon is my KIT mutation in, and what does that predict about imatinib response?
  • If my tumor progressed on treatment, was repeat testing done to look for resistance mutations?
  • If KIT is negative but GIST is suspected, were PDGFRA and SDH markers evaluated?
  • Are there exon-specific dosing or sequencing decisions I should confirm with my team?

Frequently asked questions

Does the exon number really change treatment?

Yes. Exon 9 mutations are a recognized reason to use a higher imatinib dose, and secondary exon 13/14 versus 17/18 mutations respond differently to later-line drugs. The exon is not fine print - it is the decision.

Can a negative KIT result be wrong?

Small biopsies and low-purity samples can miss mutations, and some true GISTs are KIT-negative. If the clinical picture says GIST, further testing (PDGFRA, SDHB staining) is standard.

Can someone independently review this result?

Yes. A Clarity Report can assess the exact exon finding, treatment history and resistance pattern, then return findings in writing.

Sources

Free 15-minute consultation